Liquet Medical

What Liquet Medical does

Liquet Medical is a Virginia-based, privately held medical device company founded in 2020 that develops the Versus Catheter, a patent-protected dual-tip telescoping catheter with integrated real-time pulmonary artery pressure monitoring. The device is indicated for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the pulmonary artery vasculature of adult patients and for hemodynamic assessment through direct intracardiac and pulmonary artery pressure monitoring, enabling a treatment category the company calls 'Hemodynamics-Led Thrombolysis (HLT).' The Versus Catheter is positioned as the first and only device enabling simultaneous treatment of both lungs with a single catheter, and supports both flow-directed balloon placement using the patient's natural blood flow and standard guidewire technique.

The company operates a direct-to-hospital sales model in the United States, selling the Versus Catheter to interventional cardiology departments (enabled by the first FDA 510(k) clearance in December 2024) and interventional radiology departments (enabled by a second 510(k) clearance in February 2026 for a new configuration with enhanced torque control and thicker guidewire compatibility). Targeted customers are hospital systems performing pulmonary artery catheter-directed therapy, with reference relationships at UVA Health and Sanford Health, and a stated intent to run a US IDE trial for pulmonary embolism treatment.

Liquet Medical is an early-stage company (1-10 employees) that has raised a modest disclosed funding base (a 2021 SEC Form D exempt offering, a 2022 equity round, a 2024 Lighthouse Labs investment, and 2023-2025 Virginia Venture Partners / VIPC capital) supplemented by non-dilutive Virginia Catalyst and Commonwealth Commercialization Fund grants. Revenue is not publicly disclosed; commercial sales of the Versus Catheter are at an early stage and the company is preparing for expanded indications and broader US market access.

Name

Liquet Medical

Legal name

Liquet Medical Inc.

Website

https://liquetmedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Liquet Medical is a Virginia-based, privately held medical device company that develops the Versus Catheter, a patent-protected dual-tip pulmonary artery drug delivery catheter with real-time pressure monitoring for treating pulmonary blood clots via catheter-directed thrombolysis in hospital interventional cardiology and radiology departments.

Ownership category

akta.pro rank

Product category

Vascular Interventional Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

akta.pro secondary industries

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Catheter-directed thrombolysis
• Pulmonary artery catheter
• Vascular drug delivery
• Interventional cardiology devices
• Hemodynamic monitoring devices

Headquarters

HQ city

Glen Allen

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Versus Catheter Device Sales: The company generates revenue from the sale of its FDA-cleared Versus Catheter device to hospitals and clinics in the United States. The device is indicated for controlled and selective infusion of physician-specified fluids including thrombolytics into the pulmonary artery vasculature, and for hemodynamic assessment through direct intracardiac and pulmonary artery pressure monitoring.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Liquet Medical develops and commercializes the Versus Catheter, an FDA-cleared dual-tip pulmonary artery drug-delivery catheter with integrated real-time pressure monitoring. The device is sold to hospitals and clinics for the controlled infusion of physician-specified fluids, including thrombolytics, into the pulmonary artery vasculature and for hemodynamic assessment through direct intracardiac and pulmonary artery pressure monitoring in adult patients.

Product overview

Liquet Medical offers a single core product — the Versus Catheter — a dual-tip pulmonary artery drug delivery catheter with integrated real-time pressure monitoring. The company has received two FDA 510(k) clearances for different configurations of this device: the first configuration cleared in December 2024 targets interventional cardiology, while the second configuration cleared in February 2026 expands access to interventional radiology with enhanced torque control and compatibility with thicker guidewires. The device enables a new treatment category called 'Hemodynamics-Led Thrombolysis (HLT)' that allows physicians to personalize blood clot therapy based on real-time pulmonary artery pressure data.

Differentiator

Problem solved

Functional benefit

Products and services

• Versus Catheter A dual-tip pulmonary artery drug delivery catheter with integrated real-time pressure monitoring and a flow-directed placement balloon. Indicated for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the pulmonary artery vasculature in adult patients, and for the assessment of a patient's hemodynamic condition through direct intracardiac and pulmonary artery pressure monitoring. Sold to hospitals and interventional cardiology and interventional radiology departments in the United States.
• Versus Catheter (Interventional Radiology Configuration) A second FDA 510(k)-cleared configuration of the Versus Catheter designed for interventional radiology use, with enhanced torque control and compatibility with thicker guidewires to match IR workflow preferences, while retaining the dual-tip telescoping design and integrated real-time pulmonary artery pressure monitoring.

Quantifiable outcome

• Real-time PA pressure monitoring enables objective physiologic feedback to optimize therapy decisions during blood clot treatment
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sanford HealthcoreStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. Sanford Health has been involved in the development and testing of the Versus Catheter, with a Sanford doctor featured in news coverage about the device simplifying lung blood clot treatment.
• MedTech InnovatorminorStrategic or Co-development PartnerLiquet Medical was selected as a Top 50 startup in the 2022 MedTech Innovator cohort, providing access to mentorship, industry expertise, and potential strategic partnerships within the global medtech ecosystem.
• Lighthouse LabsminorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. Lighthouse Labs is a Virginia-based life sciences accelerator/incubator.
• CVill BioHubminorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. CVill BioHub is a central Virginia life sciences and biotechnology hub.
• VirginiaBiominorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. VirginiaBio is a state-level life sciences industry organization.
• NSF ICorpsminorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. NSF I-Corps is a National Science Foundation program that helps researchers translate scientific discoveries into commercial products.
• Catalyst AcceleratorminorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. The Catalyst Accelerator supports early-stage medical technology companies.
• HSE (Healthcare Supplementary Ecosystem)minorStrategic or Co-development PartnerListed as a partner on the Liquet Medical website. HSE appears to be a healthcare ecosystem partner supporting the company's development efforts.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Inari Medical: Inari Medical developed the FlowTriever system for catheter-based thrombectomy in pulmonary embolism, making it the most direct clinical competitor to Liquet's Versus Catheter in the same PE treatment market and the same hospital buyer (interventional cardiology and IR).
• Penumbra: Penumbra's Indigo aspiration system is used for catheter-directed treatment of pulmonary embolism, directly competing with Versus in the same clinical indication, same specialty call points, and same hospital purchasing channel.
• AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for PE and other vascular thrombus, overlapping directly with Versus Catheter's catheter-based PE therapy positioning in interventional radiology and vascular surgery.

Broad incumbents

• Stryker (Neurovascular / Inari): Stryker acquired Inari Medical in 2025, giving it a large incumbent presence in catheter-directed PE therapy; the same sales channels and hospital contracts Versus is trying to access overlap with Stryker's vascular and neurovascular portfolio.
• Boston Scientific: Boston Scientific has a broad peripheral intervention and interventional cardiology portfolio that includes vascular access sheaths, guidewires, and thrombectomy-adjacent devices used in the same PE treatment procedures as the Versus Catheter.
• Medtronic: Medtronic's peripheral vascular and interventional portfolio includes catheters, guidewires, and embolic/thrombus management devices used in pulmonary embolism interventions, putting it in the same hospital buying pathway as Liquet.
• Abbott: Abbott's vascular and interventional cardiology businesses sell diagnostic and therapeutic catheters used in the cath lab and IR suite, sharing buyer relationships and procedural workflows with the Versus Catheter.
• Teleflex: Teleflex markets vascular access and interventional products (including Arrow and specialty catheters) used by interventional cardiology and IR teams, overlapping the same hospital departments Versus targets.
• Becton Dickinson (BD): BD's peripheral intervention and vascular access portfolio places it in the same hospital procurement channel for catheter-based vascular and PE procedures as Liquet Medical.
• Merit Medical Systems: Merit Medical acquired Bluegrass Vascular Technologies (where Board Chair Dr. Niederauer was previously CEO) and has a peripheral and interventional cardiology catheter portfolio, making it both a strategic acquirer reference and a direct channel peer for catheter-based vascular devices.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/liquetmedical
• Facebookfacebook.com/LiquetMedicalInc
• LinkedInlinkedin.com/company/liquet-medical-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liquet Medical